Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Non-Current Liabilities: 2017-2025

Historic Other Non-Current Liabilities for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to $10.6 million.

  • Aclaris Therapeutics' Other Non-Current Liabilities rose 6.00% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 6.00%. This contributed to the annual value of $8.7 million for FY2024, which is 40.32% up from last year.
  • According to the latest figures from Q3 2025, Aclaris Therapeutics' Other Non-Current Liabilities is $10.6 million, which was up 0.95% from $10.5 million recorded in Q2 2025.
  • Aclaris Therapeutics' Other Non-Current Liabilities' 5-year high stood at $33.1 million during Q4 2022, with a 5-year trough of $6.2 million in Q4 2023.
  • In the last 3 years, Aclaris Therapeutics' Other Non-Current Liabilities had a median value of $10.0 million in 2024 and averaged $15.3 million.
  • In the last 5 years, Aclaris Therapeutics' Other Non-Current Liabilities spiked by 636.54% in 2021 and then crashed by 81.27% in 2023.
  • Aclaris Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $28.4 million in 2021, then rose by 16.55% to $33.1 million in 2022, then plummeted by 81.27% to $6.2 million in 2023, then spiked by 40.32% to $8.7 million in 2024, then grew by 6.00% to $10.6 million in 2025.
  • Its last three reported values are $10.6 million in Q3 2025, $10.5 million for Q2 2025, and $9.0 million during Q1 2025.